Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025
Opus Genetics, Inc. RESEARCH TRIANGLE PARK, N.C., Oct. 02, 2025 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD),…
Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)
Opus Genetics, Inc. Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular…
Opus Genetics Appoints Rob Gagnon as Chief Financial Officer
Opus Genetics, Inc. Robert Gagnon, CFO, Opus Genetics Robert Gagnon, CFO, Opus Genetics RESEARCH TRIANGLE PARK, N.C., Sept.…
How viruses know what’s theirs | MSUToday
Researchers at San Diego State University and Michigan State University are shedding new light on how viruses meticulously…
Gene therapy can be less effective in women – and my research in mice brings us one step closer to understanding why
Gene therapies hold immense promise for treating sight loss. These therapies use a modified, harmless virus to deliver…
Biologic Therapeutics Market to Hit $794.5 Billion by 2029
“Driven by Rising Chronic Disease Burden and Breakthrough FDA Approvals, Biopharmaceutical Market Surges with Demand for Monoclonal Antibodies,…